Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia

Jaroslav Jelinek1*, Vazganush Gharibyan1, Marcos R. H. Estecio1, Kimie Kondo1, Rong He1, Woonbok Chung1, Yue Lu1, Nianxiang Zhang2, Shoudan Liang2, Hagop M. Kantarjian1, Jorge E. Cortes1, Jean-Pierre J. Issa1

1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, 2 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

Abstract

The epigenetic impact of DNA methylation in chronic myelogenous leukemia (CML) is not completely understood. To elucidate its role we analyzed 120 patients with CML for methylation of promoter-associated CpG islands of 10 genes. Five genes were identified by DNA methylation screening in the K562 cell line and 3 genes in patients with myeloproliferative neoplasms. The CDKN2B gene was selected for its frequent methylation in myeloid malignancies and ABL1 as the target of BCR-ABL translocation. Thirty patients were imatinib-naïve (mostly treated by interferon-alpha before the imatinib era), 30 were imatinib-responsive, 50 were imatinib-resistant, and 10 were imatinib-intolerant. We quantified DNA methylation by bisulfite pyrosequencing. The average number of methylated genes was 4.5 per patient in the chronic phase, increasing significantly to 6.2 in the accelerated and 6.4 in the blastic phase. Higher numbers of methylated genes were also observed in patients resistant or intolerant to imatinib. These patients also showed almost exclusive methylation of a putative transporter OSCP1. Abnormal methylation of a Src suppressor gene PDLIM4 was associated with shortened survival independently of CML stage and imatinib responsiveness. We conclude that aberrant DNA methylation is associated with CML progression and that DNA methylation could be a marker associated with imatinib resistance. Finally, DNA methylation of PDLIM4 may help identify a subset of CML patients that would benefit from treatment with Src/Abl inhibitors.

Introduction

DNA methylation in promoter-associated CpG islands is a powerful mechanism of gene silencing that is one of the drivers of neoplastic transformation through the inactivation of critical tumor-suppressor pathways [1]. DNA hypermethylation is commonly seen in various types of leukemia including acute myeloid leukemia [2], acute lymphoblastic leukemia [3], chronic lymphocytic leukemia [4,5,6], and it has recently been shown to predict outcomes in some patients with myelodysplastic syndrome [7,8]. Etiologically, chronic myelogenous leukemia (CML) is a homogeneous genetic disease, as it is triggered by the aberrant tyrosine kinase activity of the BCR-ABL translocation [9].

Despite genetic homogeneity, there is considerable heterogeneity in the clinical course of CML; it progresses at a varying rate from the chronic phase (CP) to the accelerated phase (AP) and eventually to the blastic phase (BP). Tyrosine kinase inhibitors such as imatinib mesylate (imatinib) are very effective in treating chronic-phase CML, but considerably less effective in treating blastic-phase CML [10]. This heterogeneity in disease progression and response to imatinib therapy is likely due to molecular events that follow the initial BCR-ABL translocation. Aberrant hypermethylation has been previously described in CML [11,12,13,14,15,16]. The translocated ABL1 promoter shows allele-specific de novo methylation early on in the course of the disease, a phenomenon that is unique to CML [14,17]. A few studies have examined the methylation status of individual tumor-suppressor genes in CML, with results ranging from rare or no hypermethylation (e.g., SFRP1, RASSF1A) [18,19] to hypermethylation at progression (e.g., CALCA, CDKN2B, EBF2, ESR, HIC1, TFAP2A, and others) [11,12,13,20]. Hypermethylation of ATG16L2 gene promoter has been associated with a poor response to imatinib treatment [20]. However, these studies have been limited by the relatively random choice of genes examined, which was based on studies of other malignancies.

Here, we report on the methylation status of a set of 10 genes. Five genes were selected based on our genome wide methylation studies in the K562 leukemia cell line [21] and 3 genes based on our genome wide screening in patients with myeloproliferative neoplasms [22]. We have also included the CDKN2B gene, deleted in K562 and frequently methylated myeloid malignancies [23], and the ABL1 gene as the target of BCR-ABL translocation. We
found that DNA methylation was strongly associated with disease progression and resistance to imatinib in CML.

**Methods**

**Patients and cell line**

We examined gDNA from peripheral blood mononuclear cells of 120 patients with CML at various phases (65 in CP, 40 in AP, and 15 in BP) that had been treated at The University of Texas MD Anderson Cancer Center (Houston, TX). The median age was 50 years (range 16–80 years), 79 patients (65%) were male. One set of samples from 30 patients that had been collected between November 1988 and June 1993 was studied to determine the effect of DNA methylation on CML progression prior to the imatinib era (i.e., imatinib-naive patients). Most of these patients had been treated with interferon-alpha-based regimens. Another set of samples from 90 patients treated in the imatinib era was obtained between July 2001 and November 2004. Of these 90 patients, 30 were imatinib-responsive (27 in CP, 2 in AP and 1 in BP), 50 were imatinib-resistant (10 in CP, 28 in AP and 12 in BP), and 10 were imatinib-intolerant (6 in CP, 4 in AP and 0 in BP). None of the patients had been previously treated with hypomethylating drugs. Clinical and hematological data of the patients are summarized in Table 1. For normal controls, peripheral white blood cells (WBC) were collected from 22 healthy volunteers (18–53 years of age). The Institutional Review Board at MD Anderson approved all protocols, and all patients gave informed consent for the collection of residual tissues as per institutional guidelines and in accordance with the Declaration of Helsinki.

The leukemia cell line K562 used in this study was obtained from the American Type Culture Collection (Manassas, VA, USA).

**Methylated CpG island amplification microarray (MCAM) analysis**

We used gDNA from the CML-derived K562 cell line [24] and, as a control, a DNA pool made from WBC of 4 healthy donors. In separate MCAM experiments (data not shown), we found minimal differences in DNA methylation of the analyzed CpG sites between CD34+ bone marrow cells and unsorted WBC, suggesting that the chosen control was appropriate for MCAM analysis. Methylated CpG island amplification (MCA) was performed as described previously [25]. Amplicons from the K562 cell line were labeled with the Cy5 dye and cohybridized against amplicons from WBC control labeled with the Cy3 dye on Agilent Technologies 4×44 K custom DNA microarrays (Agilent, Santa Clara, CA) as described previously [2]. MCAM for K562 was performed as a single array experiment. Fluorescence signals were lowess normalized and trimmed averages of normalized log2 ratios were calculated for amplicons covered by multiple probes. Hypermethylation was defined as normalized log2 ratio of Cy5/Cy3 fluorescence greater than 1 (equivalent to 2-fold and higher K562/WBC signal intensity). MCAM has been extensively validated by independent bisulfite-based methods showing the sensitivity of 88% and the specificity of 96% [26]. Enrichment for Polycomb targets was performed by comparing genes differentially methylated in the K562 cell line with the list of targets of H3K27 trimethylation in human embryonic stem cells [27] that were present on our array. The

---

**Table 1. Characteristics of the patients.**

| Parameter                  | Pre-imatinib | Imatinib era |
|----------------------------|--------------|--------------|
| Sample dates               | 11/1988–06/1993 | 07/2001–11/2004 |
| Total patients             | 30           | 90           |
| Age, years; median (range) | 42 (16–69)   | 54 (23–80)   |
| Males                      | 20 (67%)     | 58 (64%)     |
| CML stage                  |              |              |
| chronic                    | 21           | 43           |
| accelerated                | 7            | 34           |
| blastic                    | 2            | 13           |
| Imatinib status            |              |              |
| naive                      | 30           | 0            |
| responsive                 | N/A          | 30           |
| resistant                  | N/A          | 50           |
| intolerant                 | N/A          | 10           |
| Hematological parameters   |              |              |
| WBC, 10^3/μL; median (range)| 119 (2–366) | 23 (3–317)  |
| Peripheral blood blasts, %; median (range) | 2 (0–92) | 1 (0–99)  |
| Peripheral blood basophils, %; median (range) | 2 (0–22) | 3 (0–36)  |
| Hemoglobin, g/dL; median (range) | 11.4 (5.8–15.2) | 10.9 (6.8–16.6) |
| Platelets, 10^3/μL; median (range) | 259 (50–1205) | 222 (10–1245) |
| Bone marrow blasts, %; median (range) | 2 (0–91) | 2 (0–94)  |
| Bone marrow basophils, %; median (range) | 2 (0–11) | 3 (0–27)  |

[Link to Table 1: doi:10.1371/journal.pone.0022110.t001]
effect of methylation on gene expression was assessed using GNF1H data sets [28] available from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/).

DNA methylation analysis by bisulfite pyrosequencing

We isolated gDNA from peripheral blood mononuclear cells after Ficoll separation using standard phenol-chloroform extraction. We selected 10 genes and the LINE-1 repetitive element for quantitative analysis of DNA methylation by bisulfite pyrosequencing as described previously [2,29]. Our pyrosequencing assays interrogated 2–6 adjacent CpG sites close to gene transcription start site (Table 2). Methylation status of consecutive CpG sites has a high concordance in regions spanning several hundred bases [30]. Therefore, we used mean values from all pyrosequenced CpG sites as a measure of methylation of a given gene. For each assay, we determined the range of normal values by measuring the DNA methylation levels in 18–22 healthy controls. Methylation values exceeding the maximum value detected in normal controls were considered abnormal. This criterion was more stringent that the 95% confidence interval. Genomic location of the bisulfite pyrosequencing assays and the number of investigated CpG sites in each assay are shown in Table 2. The sequences of PCR primers and annealing temperatures are listed in Table S1.

Statistical analysis

Lowess normalization and analysis of MCAM data were performed as described [26]. To analyze enrichment for Polycomb targets the chi-square test was used, and odds ratio for enrichment was calculated. Pathways affected by aberrant methylation of multiple genes were identified with Ingenuity Pathway Analysis software (Ingenuity Systems, Redwood City, CA). We used the Wilcoxon signed rank nonparametric test to compare DNA methylation data between bisulfite pyrosequencing methylation data between K562 and normal white blood cells. We used the Spearman nonparametric correlation test to compare bisulfite pyrosequencing methylation data between individual genes. We used the chi-square and Fisher’s exact tests to compare DNA methylation data with clinical parameters. We performed multivariate analysis using Cox’s regression and forward stepwise likelihood ratio model to find independent prognostic variables. We used Kaplan-Meier logrank tests to calculate and generate overall survival curves for independent variables. Two-tailed P values of 0.05 or less were considered statistically significant. We used GraphPad Prism 5 (GraphPad Software, La Jolla, CA) and PASW Statistics 17.0 to perform statistical analyses.

Results

MCAM analysis

We observed hypermethylation in the K562 cell line in 4,138 of 27,890 (15%) total CpG sites analyzed by MCAM (Figure 1). When we focused on CpG sites within 500 bp from TSS, we detected hypermethylation in 1,014 of 7,246 (14%) RefSeq autosomal genes analyzed. The complete list of methylated genes is provided in Table S2. The methylated genes showed an enrichment for targets of Polycomb (PCG) silencing in embryonic stem cells. The microarray we used for MCAM could detect methylation status of 5,143 autosomal genes with available information on PCG targeting in ES cells [27]. Among 688 genes showing hypermethylation, 178 genes (25.8%) were PCG targets. Among 4,455 unmethylated genes, only 491 genes (11.0%) were PCG targets, odds ratio 2.8 (95% confidence interval 2.3 to 3.4, P<.0001, Table S3). Analysis of pathways affected by methylation of multiple genes revealed a significant enrichment for genes involved in cellular development (201 genes, P<.01), cell death (190 genes, P<.01), and gene expression (149 genes, P<.01). The list of gene categories significantly affected by DNA methylation is shown in Table S4. Based on the Gene Expression Omnibus GNF1H data sets, the hypermethylated genes as detected by MCAM also had a significantly lower expression in the K562 cell line than in normal white blood cells (P=.002; Figure 2).

Bisulfite pyrosequencing analysis

We selected 10 genes for quantitative analysis of DNA methylation by bisulfite pyrosequencing in CML patients. DYS, NPM2, OSC1, PDLIM4 and TFAP2E genes were found hypermethylated, and CDKN2B [p15INK4B], homozygously deleted in the K562 leukemia cell line. ABL1 is the subject of BCR-ABL translocation and is methylated exclusively on the Philadelphia chromosome. CDH13, PGR-A and B isoforms were identified by a genome wide screening as hypermethylated in patients with myeloproliferative neoplasms [22]. We also analyzed methylation of the LINE-1 repetitive element, as a surrogate marker of genomic methylation [31]. A summary of the results of the DNA methylation analysis in 120 patients with CML is shown in Table 3. The most frequently methylated genes in more than 70% of investigated CpG sites have a high concordance in regions spanning several hundred bases [30]. Therefore, we used mean values from all pyrosequenced CpG sites as a measure of methylation of a given gene. For each assay, we determined the range of normal values by measuring the DNA methylation levels in 18–22 healthy controls. Methylation values exceeding the maximum value detected in normal controls were considered abnormal. This criterion was more stringent that the 95% confidence interval. Genomic location of the bisulfite pyrosequencing assays and the number of investigated CpG sites in each assay are shown in Table 2. The sequences of PCR primers and annealing temperatures are listed in Table S1.

Table 2. Genomic location of bisulfite pyrosequencing assays.

| Gene  | Location of pyrosequencing target (hg18) | Distance from TSS | CpG sites in assay |
|-------|----------------------------------------|-------------------|--------------------|
| ABL1  | chr9:132,700,627–132,700,645            | –24 to –14        | 3                  |
| CDKN2B| chr16:81,218,151–81,218,189            | +74 to +102       | 6                  |
| DYS   | chr9:21,999,154–21,999,185             | +127 to +147      | 4                  |
| NPM2  | chr10:5,458,436–10,5,458,480          | –27 to +17        | 4                  |
| OSCP1 | chr1:36,688,776–36,688,815             | –37 to –20        | 5                  |
| PDLIM4| chr5:131,621,029–131,621,064          | –221 to –192      | 6                  |
| PGR-A | chr11:100,504,896–100,504,924         | +261 to +289      | 4                  |
| PGR-B | chr11:100,505,573–100,505,605         | +860 to +892      | 4                  |
| TFAP2E| chr1:35,811,437–35,811,445            | –121 to –113      | 2                  |

doi:10.1371/journal.pone.0022110.t002
in methylation of the LINE-1 repetitive element above the normal range. However, only 4 patients (3%) showed LINE-1 methylation below the normal range. The differences in LINE-1 methylation between individual stages of CML were not significant (Table S5).

DNA methylation is increased in advanced CML

Five of the 10 studied genes showed a significant methylation increase in CML progressed to AP or BP stages. These included CDKN2B, OSCP1, PGR5, PGR5 and TFAP2E genes (Table 3). We next calculated the sums of methylated and unmethylated genes in individual patients and analyzed the proportions of methylated and unmethylated genes in CML stages. On average, 4.5 genes were methylated in CP, 6.2 genes in AP and 6.8 genes in BP (Table 4). The increase in the number of methylated genes in advanced stages was statistically significant \( (P<.0001, \text{chi-square test}) \). Of 64 patients in CP, 1 patient (2%) had no hypermethylated gene and 21 patients (33%) had more than 5 hypermethylated genes. Of 41 patients in AP, no patient (0%) had zero hypermethylated genes and 25 patients (61%) had more than 5 hypermethylated genes. Of 15 patients in BP, no patient (0%) had no hypermethylated gene and 12 patients (80%) had more than 5 hypermethylated genes. There was no significant difference in overall survival between 35 CP patients with 0–4 hypermethylated genes and 29 CP patients with 4–10 hypermethylated genes. Methylation levels showed positive correlations between individual genes (Table S6). Methylation of the DPP3 gene was significantly correlated with 6 other genes, suggesting this gene may be a part of a potential hypermethylator phenotype and a shared etiology for increased methylation in a subset of affected cases. On the other hand, the PDLIM4 gene stood out showing no significant correlation with any of the other analyzed genes.

DNA methylation is increased in imatinib resistant and intolerant patients

To assess a possible epigenetic component of imatinib resistance, we compared DNA methylation in patients responsive, intolerant and resistant to imatinib. Patients in CP that were responsive to imatinib had on average 3.9 methylated genes, while patients intolerant or resistant to imatinib had 6.3 or 5.4 methylated genes, respectively \( (P=.0004, \text{chi-square test}) \). A similar increase in the number of methylated genes in patients intolerant or resistant to imatinib was also observed in AP, but not in BP (Table 5). When we analyzed individual genes, the frequency of aberrant methylation of OSCP1 and NPM2 was significantly higher in resistant and intolerant patients than in responsive patients. In the subset of CP patients, aberrant methylation of OSCP1 was seen only in the patients that were resistant or intolerant to imatinib (Table S7).

We could not assess the relationship between resistance to imatinib, DNA methylation and ABL1 mutations, since we had data on ABL1 mutational status for 10 patients only. Two patients were responsive to imatinib, negative for ABL1 mutations. They had 2 and 5 genes hypermethylated, respectively; however, they did not show hypermethyltion of OSCP1 or PDLIM4. One patient was intolerant to imatinib and negative for ABL1 mutations. The patient had 6 hypermethylated genes, however, no hypermethylation of OSCP1 or PDLIM4. Seven patients with known mutational status of ABL1 were resistant to imatinib. Three of them had mutations in ABL1, F317L, F359V and a mutation in codon 355, respectively. These patients had 4, 6 and 6 hypermethylated genes, respectively. None of these patients showed hypermethylation of
Four imatinib-resistant patients were negative for ABL1 mutations. They had 5, 7, 8 and 9 hypermethylated genes. Interestingly, three of these 4 patients had hypermethylated the OSCP1 gene and two had also hypermethylated the PDLIM4 gene.

DNA methylation and outcome

Having established that DNA methylation is increased in more advanced stages of CML and in patients resistant or intolerant to imatinib, we used multivariate analysis to examine if aberrant methylation is an independent prognostic variable. Since imatinib treatment changed radically the outcome of CML, we analyzed separately the groups of patients treated before and in the imatinib era (Table 6). Hypermethylation of OSCP1 and PDLIM4 genes were negative risk factors in the pre-imatinib era patients (hazard ratio 9.6 and 8.1, respectively, \( P = 0.001 \)). Median survival was 1 year for OSCP1-methylated and 0.6 years for PDLIM4-methylated patients, while the patients with no methylation had median survival of 4.9 years (Fig. 3). Overall survival of the second group of 90 patients diagnosed and treated after 2001 (imatinib era) is shown in Fig. 4 and Fig. 5. Advanced CML stage (hazard ratio 4.0, \( P < 0.001 \), resistance or intolerance to imatinib (hazard ratio 5.4, \( P = 0.002 \)) and hypermethylation of the PDLIM4 gene (hazard ratio 2.7, \( P = 0.003 \)) were independent prognostic variables (Table 6 and Figure 4). Median survival of the patients with hypermethylated PDLIM4 was 0.9 years while it was 3.9 years in the patients where PDLIM4 methylation was within the normal range (Figure 5). When we restricted the analysis to 30 imatinib-responsive patients only, 3 deaths were observed in 26 patients with PDLIM4 methylation within normal range, while 1 death was observed in 4 patients with hypermethylated PDLIM4. However, the difference in survival was not statistically significant, possibly due to small number of patients and events. Methylation status of the LINE-1 repetitive element did not show any association with the outcome or the stage of the disease.

Discussion

In this study, we have shown that aberrant DNA methylation of multiple genes characterizes advanced stages of CML and the disease when resistant to imatinib. Our interpretation is that the disease progression is associated with epigenetic changes including aberrant DNA methylation. We speculate that epigenetically mediated silencing of genes involved in drug transport may also affect the responsiveness of leukemic cells to imatinib. Given that CML starts as a genetically homogeneous disease, one can hypothesize that disease progression and clinical heterogeneity in CML are related to epigenetic factors including DNA hypermethylation. Our data extend previous observations on DNA methylation in CML and identify multiple new biomarkers in the disease. Of the genes specifically studied here, some may in fact contribute to the pathophysiology of disease progression. For instance, PDLIM4, also known as RIL, is a LIM domain protein that has tumor-suppressor and pro-apoptotic properties. We have previously described a significant correlation between methylation and silencing of this gene [32]. PDLIM4 was found hypermethylated and silenced in prostate cancer. Restoration of its expression suppressed tumor growth in xenografts [33]. A recent report suggests that PDLIM4 is important for inactivation of Src and that epigenetic silencing of PDLIM4 may contribute to aberrant

### Table 3. DNA methylation in CML patients.

| Gene | Cutoff* (%) methylation | CP (n = 64) | AP (n = 41) | BP (n = 15) | Total (n = 120) | P value** |
|------|-------------------------|------------|------------|------------|----------------|----------|
| ABL1 | 9                       | 52 (81)    | 37 (90)    | 14 (93)    | 103 (86)       | NS       |
| CDH13| 8                       | 47 (73)    | 34 (83)    | 14 (93)    | 95 (79)        | NS       |
| CDKN2B| 7                      | 2 (3)      | 7 (17)     | 4 (27)     | 13 (11)        | 0.009    |
| DYS | 7                       | 30 (47)    | 23 (56)    | 12 (80)    | 65 (54)        | NS       |
| NPM2 | 4                       | 45 (70)    | 32 (78)    | 12 (80)    | 89 (74)        | NS       |
| OSCP1| 4                       | 10 (16)    | 19 (46)    | 7 (47)     | 36 (30)        | 0.001    |
| PDLIM4| 33                     | 8 (13)     | 12 (29)    | 5 (33)     | 25 (21)        | NS       |
| PGRA | 6                       | 36 (56)    | 33 (80)    | 10 (67)    | 79 (66)        | 0.038    |
| PGRB | 11                      | 25 (39)    | 24 (59)    | 13 (87)    | 62 (52)        | 0.002    |
| TFAP2E| 20                     | 32 (50)    | 32 (78)    | 11 (73)    | 75 (63)        | 0.010    |

*The highest methylation value observed in normal controls.  **Chi-square test.

### Table 4. Methylation and CML stage.

| Stage | Sum of methylated genes | Sum of unmethylated genes | P value | Average of methylated genes per patient |
|-------|--------------------------|---------------------------|---------|----------------------------------------|
| CP    | 287                      | 353                       |         | 4.5                                    |
| AP    | 253                      | 157                       | <0.0001 | 6.2                                    |
| BP    | 102                      | 48                        |         | 6.8                                    |

The OSCP1 or PDLIM4 gene. Four imatinib-resistant patients were negative for ABL1 mutations. They had 5, 7, 8 and 9 hypermethylated genes. Interestingly, three of these 4 patients had hypermethylated the OSCP1 gene and two had also hypermethylated the PDLIM4 gene.

DNA methylation and outcome

Having established that DNA methylation is increased in more advanced stages of CML and in patients resistant or intolerant to imatinib, we used multivariate analysis to examine if aberrant methylation is an independent prognostic variable. Since imatinib treatment changed radically the outcome of CML, we analyzed separately the groups of patients treated before and in the imatinib era (Table 6). Hypermethylation of OSCP1 and PDLIM4 genes were negative risk factors in the pre-imatinib era patients (hazard ratio 9.6 and 8.1, respectively, \( P = 0.001 \)). Median survival was 1 year for OSCP1-methylated and 0.6 years for PDLIM4-methylated patients, while the patients with no methylation had median survival of 4.9 years (Fig. 3). Overall survival of the second group of 90 patients diagnosed and treated after 2001 (imatinib era) is shown in Fig. 4 and Fig. 5. Advanced CML stage (hazard ratio 4.0, \( P < 0.001 \), resistance or intolerance to imatinib (hazard ratio 5.4, \( P = 0.002 \)) and hypermethylation of the PDLIM4 gene (hazard ratio 2.7, \( P = 0.003 \)) were independent prognostic variables (Table 6 and Figure 4). Median survival of the patients with hypermethylated PDLIM4 was 0.9 years while it was 3.9 years in the patients where PDLIM4 methylation was within the normal range (Figure 5). When we restricted the analysis to 30 imatinib-responsive patients only, 3 deaths were observed in 26 patients with PDLIM4 methylation within normal range, while 1 death was observed in 4 patients with hypermethylated PDLIM4. However, the difference in survival was not statistically significant, possibly due to small number of patients and events. Methylation status of the LINE-1 repetitive element did not show any association with the outcome or the stage of the disease.

Discussion

In this study, we have shown that aberrant DNA methylation of multiple genes characterizes advanced stages of CML and the disease when resistant to imatinib. Our interpretation is that the disease progression is associated with epigenetic changes including aberrant DNA methylation. We speculate that epigenetically mediated silencing of genes involved in drug transport may also affect the responsiveness of leukemic cells to imatinib. Given that CML starts as a genetically homogeneous disease, one can hypothesize that disease progression and clinical heterogeneity in CML are related to epigenetic factors including DNA hypermethylation. Our data extend previous observations on DNA methylation in CML and identify multiple new biomarkers in the disease. Of the genes specifically studied here, some may in fact contribute to the pathophysiology of disease progression. For instance, PDLIM4, also known as RIL, is a LIM domain protein that has tumor-suppressor and pro-apoptotic properties. We have previously described a significant correlation between methylation and silencing of this gene [32]. PDLIM4 was found hypermethylated and silenced in prostate cancer. Restoration of its expression suppressed tumor growth in xenografts [33]. A recent report suggests that PDLIM4 is important for inactivation of Src and that epigenetic silencing of PDLIM4 may contribute to aberrant
activation of Src in cancer [34]. Hypermethylation of PDLIM4 in our sets of CML patients had a negative prognostic impact independent of the response to imatinib. We suggest that CML patients with epigenetically silenced PDLIM4 may particularly benefit from treatment with Src/Abl inhibitors.

Table 5. Methylation and response to imatinib.

| Stage | Imatinib response | Sum of methylated genes | Sum of unmethylated genes | P value | Average of methylated genes per patient |
|-------|-------------------|-------------------------|--------------------------|---------|----------------------------------------|
| All stages | Responsive | 120 | 180 | <0.0001 | 4.0 |
| | Intolerant | 62 | 38 | | 6.2 |
| | Resistant | 318 | 182 | | 6.4 |
| CP | Responsive | 104 | 166 | 0.0004 | 3.9 |
| | Intolerant | 38 | 22 | | 6.3 |
| | Resistant | 54 | 46 | | 5.4 |
| AP | Responsive | 8 | 12 | 0.0498 | 4.0 |
| | Intolerant | 24 | 16 | | 6.0 |
| | Resistant | 186 | 94 | | 6.6 |
| BP | Responsive | 8 | 2 | NS | 8.0 |
| | Intolerant | 0 | 0 | | N/A |
| | Resistant | 78 | 42 | | 6.5 |

doi:10.1371/journal.pone.0022110.t005

Figure 3. Methylation of OSCP1 and PDLIM4 in CML patients from the pre-imatinib era. Hypermethylation of OSCP1 (top) and PDLIM4 (bottom) is associated with shortened survival. Green line, methylation within normal range. Red line, hypermethylation. doi:10.1371/journal.pone.0022110.g003

Figure 4. Advanced stage of CML and resistance or intolerance to imatinib are associated with shortened survival. Top graph, green, chronic phase; red, accelerated phase; black, blastic phase. Bottom graph, green, imatinib-responsive patients; red, patients resistant or intolerant to imatinib. The figure shows 90 CML patients (43 CP, 34 AP, 13 BP) from the imatinib era. doi:10.1371/journal.pone.0022110.g004
However, suppressor gene is frequently reported in myeloid malignancies patients in our study, and its methylation did not show an of this phenotype remain unknown, and whether the same factors methylator phenotype described in colon cancer [45]. The causes methylation was likely caused by patient-specific pressures to chromosomal location, or function, and so this concordant methylation as concordant methylation also occurred within each genes tested, which cannot be explained simply by phase-specific defects in CML as is the case in prostate and breast cancer [35].

This gene codes for an organic solute carrier protein with broad substrate specificity [44]. The gene product may be involved in the transport of imatinib to target cells and its silencing may thus contribute to imatinib resistance.

Aberrant methylation of other genes likely represents passenger epigenetic defects that reflect the pressures to increase promoter DNA methylation in neoplastic cells. NPM2, or nucleophosmin 2, is involved in forming nucleolus-like bodies in oocytes [37]. It is aberrantly methylated in patients with acute myeloid leukemia [2] and melanoma [38]. Progesterone receptor methylation has been reported in leukemia [2] and solid cancers [39,40,41,42]. The role of DPYS, or dihydropyrimidinase, in the hematopoietic system is currently unknown, and it may simply be a marker of methylation defects in CML as is the case in prostate and breast cancer [35].

Methylation of the OSCP1 gene (formerly known as C10orf102 or NOL1) and its strong association with resistance to imatinib is intriguing. Aberrant methylation of OSCP1 has been shown in nasopharyngeal carcinoma [43] and acute myeloid leukemia [2]. This gene codes for an organic solute carrier protein with broad substrate specificity [44]. The gene product may be involved in the transport of imatinib to target cells and its silencing may thus contribute to imatinib resistance.

We found strong concordant methylation for several of the genes tested, which cannot be explained simply by phase-specific methylation as concordant methylation also occurred within each phase. The genes involved do not share features, such as structure, chromosomal location, or function, and so this concordant methylation was likely caused by patient-specific pressures to increase DNA methylation, a phenomenon akin to the CpG island methylator phenotype described in colon cancer [45]. The causes of this phenotype remain unknown, and whether the same factors that lead to it in solid tumors are involved in leukemia pathogenesis or progression remains to be determined.

Complex changes of DNA methylation in cancer can be summarized as focal hypermethylation of promoter CpG islands and global hypomethylation elsewhere, including repetitive elements [46]. We have previously shown that methylation of the LINE-1 repetitive element in cancer and leukemia was highly variable [47]. In this paper, we found that LINE-1 was methylated above the normal range in 55% of CML patients and only 3% of patients showed LINE-1 hypomethylation. This is in contrast with reports of LINE-1 hypomethylation and transcriptional activation in CML and progressive hypomethylation in the advanced phase of the disease [48,49].

Further analysis of the data on higher DNA methylation of OSCP1 and other genes in imatinib-resistant patients is warranted. It is possible that gene silencing provides an alternative to BCR-ABL mutations in conferring imatinib resistance. Indeed, only about 50% of imatinib resistance can be conclusively traced to acquired mutations [50]. It will therefore be worthwhile to study mutations and methylation simultaneously and determine whether there is an inverse correlation between the two events, and whether it is relevant to resistance to other tyrosine kinase inhibitors. It is also interesting to consider the fact that DNA methylation can be partially reversed by treatment with decitabine or azacitidine. Decitabine has demonstrated single-agent activity in CML [29], and a combination of decitabine and imatinib has shown a promising response rate in AP and BP [51]. Given that many patients with blast-phase CML continue to die of their disease, such drug combinations may be relevant even after therapy with second-generation tyrosine kinase inhibitors.

Supporting Information

Table S1 Bisulfite PCR and pyrosequencing primers. (XLS)

Table S2 List of genes methylated in the K562 cell line. Genomic coordinates are based on the March 2006 Assembly (NCBI36/hs18). XmaFrag_Start, coordinate of the 5’ XmaI site. XmaFrag_End, coordinate of the 3’ XmaI site. Gene1, gene with the start site closest to the 5’ XmaI site. Gene2, gene with the start site closest to the 3’ XmaI site. Distance2TSS_Gene1, distance to transcription start site closest to the 5’ XmaI site. Distance2TSS_Gene2, distance to transcription start site closest to the 3’ XmaI site. Signal_Intensity_Average, average log2 of signal intensity of probes covering the XmaI fragment. Log2_Ratio_K562vsControl, average log2 ratio of Cy5/Cy3 signal intensity of probes covering the XmaI fragment. (XLS)
Table S3 Genes methylated in the K562 leukemia cell line are enriched for targets of Polycomb in ES cells.

Table S4 Gene categories affected by DNA methylation in K562.

Table S5 LINE-1 methylation.

Table S6 Spearman correlation between methylation of different genes. In each cell, the top number is the correlation coefficient r. The bottom number is a P value. To correct for multiple comparisons, P<.001 was considered significant.

Table S7 Methylation of individual genes and the response to imatinib.

Acknowledgments

We thank Lionel Santibañez for editorial help.

Author Contributions

Conceived and designed the experiments: J-PJI JJ. Performed the experiments: VG KK MRHE RH WC JJ. Analyzed the data: JJ VG MRHE YL. Contributed reagents/materials/analysis tools: NZ SL. Wrote the paper: J-PJI JJ.

References

1. Toyota M, Issa JP (2005) Epigenetic changes in solid and hematopoietic tumors. Semin Oncol 32: 521–530.
2. Kroeger H, Jelink J, Esteco MR, He R, Kondo K, et al. (2008) Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood: 1136: 1366–1373.
3. Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, et al. (2008) Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute myeloid leukemia. Leukemia 22: 1529–1538.
4. Rush LJ, Raval A, Funachi P, Johnson AJ, Smith L, et al. (2004) Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res 64: 2414–2433.
5. Liu TH, Raval A, Chen SS, Matkovic JJ, Byrd JC, et al. (2006) CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res 66: 653–658.
6. Kanduri M, Cahill N, Goransson H, Enstrom C, Ryan F, et al. (2010) Differential genome-wide array-based methylation profiles in prognostic subsets of AML. Blood 115: 296–305.
7. Jiang Y, Dubnar A, Gondek LP, Mohan S, Rataul M, et al. (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood: 113: 1315–1325.
8. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, et al. (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28: 603–613.
9. Daley GQ, Bhur同类 D (1988) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210Bcr-Abl protein. Proc Natl Acad Sci U S A 85: 9312–9316.
10. Quintas-Cardama A, Kantarjian H, Cortes J (2009) Imatinib and beyond–exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 6: 1378–1385.
11. Nelkin BD, Przepiorka D, Burke PJ, Thomas ED, Baylin SB (1991) Abnormal DNA methylation is frequent and associated with persistent Philadelphia chromosome in chronic myeloid malignancy is frequent and associated with poor prognosis. Clin Cancer Res 13: 5048–5053.
12. Issa JP, Zehnbauer BA, Kaufmann SH, Bel M, Baylin SB (1997) HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res 57: 1678–1681.
13. Nguyen TT, Mohrbracher AF, Tsai YC, Groffen J, Heisterkamp N, et al. (2000) Quantitative measure of c-abl and p130 c-abl hypermethylation in chronic myelogenous leukemia: biological implications. Blood: 95: 2990–2992.
14. Roman-Gonzalez J, Castillo-Ja JA, Jimenez A, Cervantes F, Boque C, et al. (2003) Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. J Clin Oncol 21: 1472–1479.
15. Spruck CH, Holsboer TL, Vio Tim A, Parker A, Ostric DG, et al. (2007) Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res 13: 5048–5053.
16. Zon M, Ben-Yehuda D, Avraham A, Cohen O, Wetzler M, et al. (1994) Progressive de novo DNA methylation at the h-crb1 locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci U S A 91: 10722–10726.
17. Pehivan M, Sercan Z, Sercan HO (2009) dFR1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myelogenous leukemia. Leuk Res 33: 1062–1067.
18. Avramouli A, Tsocha S, Mandala E, Katsoudri E, Ioannou M, et al. (2009) Methylation status of RASSF1A in patients with chronic myeloid leukemia. Cancer Res 69: 1130–1132.
19. Dunwell T, Hesson L, Rauch TA, Wang L, Clark RE, et al. (2010) A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. Mol Cancer 9: 44.
42. Widschwendter A, Muller HM, Fieg H, Ivarson L, Wiedemann A, et al. (2004) DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res 10: 365–371.
43. Nie X, Zhang B, Li X, Xiang J, Xiao B, et al. (2003) Cloning, expression, and mutation analysis of NOR1, a novel human gene down-regulated in HNE1 naopharyngeal carcinoma cell line. J Cancer Res Clin Oncol 129: 410–414.
44. Kobayashi Y, Shibusawa A, Saito H, Ohishi N, Ohbayashi M, et al. (2005) Isolation and functional characterization of a novel organic solute carrier protein, hOSCP1. J Biol Chem 280: 32332–32339.
45. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, et al. (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96: 8681–8686.
46. Baylin SB, Herman JG, Graff JR, Vertino PM, Isa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141–196.
47. Estecio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, et al. (2007) LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS ONE 2: e399.
48. Roman-Gomez J, Jimenez-Velasco A, Aguirre X, Cervantes F, Sanchez J, et al. (2005) Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24: 7213–7223.
49. Roman-Gomez J, Jimenez-Velasco A, Aguirre X, Castillejo JA, Navarro G, et al. (2008) Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia. Leuk Res 32: 487–490.
50. Jabbour E, Cortes J, Kantarjian H (2009) Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 4: 3–10.
51. Oki Y, Kantarjian HM, Ghahriyan V, Jones H, O’Brien S, et al. (2007) Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109: 899–906.